Navigation Links
FDA Approves Novel Creation of Imitrex? Injection for Migraine

The Food and Drug Administration (FDA) has approved a creation of the Imitrex Injection that enables patients to consume a 4mg dosage, // named as the Imitrex STAT dose System ? used to treat severe migraines in adults in the presence or absence of aura.

Migraine is known to be a common ailment for as many as 28 million Americans suffers from migraine headaches. The treatments for migraines differ according to the intensity of the attack and hence vary from patient to patient. Since migraine attacks vary in its severity, it is imperative to enable patients with various treatment options.

Though oral medication is effective in certain cases, sometimes an injection might be more appropriate when the intensity of the attack is severe.

Morning migraines begin for patients as early as the waking hours when patients awaken with a moderate to severe headache. Statistics have it that an average of 48% headaches attack between 4 am and 9 am.

Migraines are also accompanied by nausea and vomiting in almost 48% of the cases. Migraines are also known to accelerate in intensity, and in such cases an injection is known to alleviate the pain.

Robert Kaniecki, MD, director of The Headache Center at the University of Pittsburgh and assistant professor of neurology, said, “ Imitrex Injection is now an effective option for patients with certain types of migraines and Migraine patients who experience nausea or vomiting with their headaches, often require an injection, since oral treatments are typically not well tolerated by these patients. Additionally, injections bypass the digestive system and enter the bloodstream quickly, which is especially important for treating certain migraine attacks, such as morning and rapidly escalating migraines.”


'"/>




Page: 1

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
Breaking Medicine Technology:Reportlinker Adds Medical Fiber Optics - A World Market Analysis 2Reportlinker Adds Medical Fiber Optics - A World Market Analysis 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 4Reportlinker Adds Medical Fiber Optics - A World Market Analysis 5Reportlinker Adds Medical Fiber Optics - A World Market Analysis 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 2Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 3Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 4Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 5Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 6Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 7Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 8Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 9Celator 28R 29 Pharmaceuticals Presents Data on the Activity of CPX 351 Against Leukemia at the European Hematology Association Congress 12509 1Celator 28R 29 Pharmaceuticals Presents Data on the Activity of CPX 351 Against Leukemia at the European Hematology Association Congress 12509 2Celator 28R 29 Pharmaceuticals Presents Data on the Activity of CPX 351 Against Leukemia at the European Hematology Association Congress 12509 3Rights Access to Healthcare Providers of Choice at Risk 48146 1Rights Access to Healthcare Providers of Choice at Risk 48146 2Rights Access to Healthcare Providers of Choice at Risk 48146 3Generic Erosion Increased Competition and Cost Consciousness Will Reduce Overall Asthma Drug Market by 241 8 Billion from 2008 to 2018 48141 1Generic Erosion Increased Competition and Cost Consciousness Will Reduce Overall Asthma Drug Market by 241 8 Billion from 2008 to 2018 48141 2